https://pressroom.prlog.org/Onconostic/ About Onconostic Technologies / 3NDx - Onconostic Technologies' patented precision oncology test identifies if tumor plasticity has been turned "on", predicts cancer metastasis and recurrence risk, and identifies which patients may derive the greatest clinical benefit of targeted drug therapy. https://www.prlog.org/13023854-veresca-foxc1-prognostic-and-predictive-data-in-oral-cancer-presented-at-nature-conference-2024.html Onconostic Technologies-3N Diagnostics Group (OT/3NDx), an emerging leader in precision oncology diagnostics, today announced clinical validation of the pan-cancer, tissue agnostic utility of VERESCA based on detection of FOXC1 protein in oral cancer.Mon, 10 Jun 2024 14:00:00 GMT https://www.prlog.org/13022770-veresca-foxc1-phase-iii-triple-negative-breast-cancer-test-data-presented-at-asco-2024.html Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced study results from the Phase III GEICAM/CIBOMA clinical trial involving patients diagnosed with triple-negative breast cancer (TNBC).Fri, 31 May 2024 19:45:00 GMT https://www.prlog.org/13019912-veresca-foxc1-ihc-precision-oncology-test-phase-3-trial-data-to-be-presented-at-asco-2024.html Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced that new breast cancer data will be highlighted in a Rapid Oral Abstract Session at the 2024 American Society of Clinical Oncology (ASCO)..Thu, 09 May 2024 14:29:58 GMT